This multi-center, randomized controlled study aims to evaluate the effects of pentoxifylline on proteinuria in Korean type 2 diabetic patients.
The investigators will recruit adults patients with type 2 diabetes aged over 20 years with spot urine albumin to creatinine ratio over 30mg/g in two consecutive measurements. Enrolled patients will be randomly assigned to receive pentoxifylline (400mg three times daily) or placebo for 24 weeks. Fasting blood and spot urine will be collected at baseline, 12 weeks and 24 weeks. The investigators will evaluate the impact of pentoxifylline on proteinuria in type 2 diabetic patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
174
Pentoxifylline 400mg three times a day
placebo tablet three times a day
Ajou University Hospital
Suwon, South Korea
Percentage Change in Proteinuia
Changes of urine protein to creatinie ratio from baseline to 24 weeks
Time frame: baseline and 24 weeks
Percentage Change in Albuminuria
Changes of urine albumin to creatinie ratio from baseline to 24 weeks
Time frame: baseline and 24 weeks
Mean Change of eGFR
changes in eGFR from baseline to 24 weeks
Time frame: baseline and 24 weeks
Mean Change of Creatinine
changes serum creatinine from baseline to 24 weeks
Time frame: baseline and 24 weeks
Mean Change of Fasting Glucose
changes serum fasting glucose from baseline to 24 weeks
Time frame: baseline and 24 weeks
Mean Change of TNF-a
changes in TNF-a from baseline to 24 weeks
Time frame: baseline and 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.